AMIKACIN

100 mg-250 mg-500 mg

USUAL DILUENTS
NS, D5W
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

To reduce the development of drug-resistant bacteria and maintain the

effectiveness of amikacin and other antibacterial drugs, amikacin should be
used only to treat or prevent infections that are proven or strongly suspected to
be caused by bacteria.
Admixture:
[0-1000 mg] [100 ml] [30 minutes]
Infusion rate range: 30 to 60 minutes.

STABILITY
Label: Refrigerate.
---- Storage/Stability ----
Amikacin sulfate is stable for 24 hours at room temperature at concentrations of 0.25 and 5.0 mg/mL in the following
solutions:
5% Dextrose Injection, USP
5% Dextrose and 0.2% Sodium Chloride Injection, USP
5% Dextrose and 0.45% Sodium Chloride Injection, USP
0.9% Sodium Chloride Injection, USP
Lactated Ringer’s Injection, USP
Normosol®-M in 5% Dextrose Injection
Normosol®-R in 5% Dextrose Injection
STABILITY DATA:

Stability Reconstitute
Stability Room d P-Insert
Drug Refrigerated Temp. Vial/Powder Notes Updated
Amikacin should not be physically premixed
with other drugs but should be administered
See separately according to the recommended 01 20
Amikacin comments 24 hours Solution dose and route. 16
Comments:
Refrigerated: In the above solutions with amikacin sulfate injection concentrations of 0.25 and 5 mg/mL, solutions
aged for 60 days at 4°C and then stored at 25°C had utility times of 24 hours.
At the same concentrations, solutions frozen and aged for 30 days at -15°C, thawed, and stored at 25°C had utility
times of 24 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration
whenever the solution and container permit.

Aminoglycosides administered by any of the above routes should not be physically premixed with other drugs but
should be administered separately.

Because of the potential toxicity of aminoglycosides, “fixed dosage” recommendations which are not based upon body